Graham Capital Management’s Caribou Biosciences CRBU Stock Holding History

Graham Capital Management’s Portfolio CRBU Stock Details CRBU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$274K	Buy	155,914 +117,163	+302%	+$232K	0.01%	932
2026 Q1	$73.6K	Sell	38,751 -68,502	-64%	-$118K	﹤0.01%	1070
2025 Q4	$171K	Sell	107,253 -21,099	-16%	-$44.3K	﹤0.01%	1077
2025 Q3	$299K	Buy	+128,352	New	+$242K	﹤0.01%	858
2025 Q2	–	Sell	-74,225	Closed	-$67.8K	–	1338
2025 Q1	$67.8K	Buy	+74,225	New	+$96.5K	﹤0.01%	1225

Other funds holding CRBU

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Graham Capital Management's CRBU Position: Q2 2026 in Review

Graham Capital Management increased its Caribou Biosciences (CRBU) stake by 302% in Q2 2026, buying an estimated $232K and bringing the position to 155,914 shares worth $274K. The position accounts for 0.01% of the portfolio, ranked #932.

Graham Capital Management first reported a position in CRBU in Q1 2025 and has held it in 5 quarters since. The position peaked at $299K in Q3 2025. 137 funds tracked by Wall St. Rank hold CRBU as of Q2 2026.

Graham Capital Management held 155,914 shares of Caribou Biosciences worth $274K as of Q2 2026.
Graham Capital Management bought 117,163 Caribou Biosciences shares in Q2 2026, an estimated $232K.
Caribou Biosciences made up 0.01% of Graham Capital Management's portfolio in Q2 2026, its #932 holding.
Graham Capital Management first reported a position in Caribou Biosciences in Q1 2025 and has held it in 5 quarters since.
Graham Capital Management's Caribou Biosciences position peaked at $299K in Q3 2025.
137 funds tracked by Wall St. Rank held Caribou Biosciences as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.